^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
GD2-SADA
i
Other names: GD2-SADA
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Y-mAbs Therap
Drug class:
GD2 ganglioside inhibitor
Related drugs:
2ms
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 (clinicaltrials.gov)
P1, N=60, Recruiting, Y-mAbs Therapeutics | Trial completion date: Jan 2025 --> Apr 2027 | Trial primary completion date: Mar 2024 --> Mar 2027
Trial completion date • Trial primary completion date • Metastases
|
GD2-SADA
2years
Self-assembling and disassembling (SADA) domain is critical to the binding, and anti-tumor efficacy of GD2-SADA (AACR 2022)
The tetramerizing function of the SADA domain is critically important to the binding activity and anti-tumor efficacy of GD2 SADA. These data confirm that the SADA domain increases tumor antigen binding, uptake and persistence in tumor tissue, and markedly improves anti-tumor responses in preclinical models.
Clinical
|
TP53 (Tumor protein P53)
|
TP53 expression
|
GD2-SADA
Share via
